ReForm Biologics, MilliporeSigma ink license agreement

By The Science Advisory Board staff writers

February 10, 2020 -- ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications.

The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use, with MilliporeSigma funding the effort and taking responsibility for global marketing, manufacturing, and sale of the excipients to its customers. ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics' technology, it said.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here